Definitive Contract HHSN261201200048C

This is a delivery order under the Toxicology of Drugs Developed for Cancer Patients contract vehicle, awarded by the National Cancer Institute (NCI) to Battelle Memorial Institute. The $248,269.21 cost-plus-fixed-fee contract is for a pre-clinical toxicity study to characterize the toxicity of potential anticancer compounds following multiple dose administration to rats. The contract runs from January 18, 2017 to June 30, 2018. No set-aside designation is mentioned. Battelle frequently serves...

This contract was awarded by the National Cancer Institute, a civilian agency, to Radiomedix, Inc., a small disadvantaged business, for the Targeted Radionuclide Therapy of Neuroendocrine Tumors Using Pb212-Octreotate Analogs project. The contract has a ceiling value of $298,132.00 and was awarded under the Small Business Innovation Research (SBIR) Program Phase I. The contract is a Definitive Contract with a Firm Fixed Price pricing type and has an ultimate completion date of August 18, 2017.

<p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Oncotherapeutica, Inc. for the development of a &quot;Prostate Cancer Selective Radioactive Prodrug&quot;. This $298,882 Firm Fixed Price contract was awarded on September 19, 2016 and has a completion date of November 18, 2017. The contract is designated as a Total Small Business set-aside.</p>

This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the IIT Research Institute (IITRI), a non-profit contract research organization. The $4,145 contract is for a pre-clinical toxicology study of a drug developed for cancer patients, as part of the Toxicology of Drugs Developed for Cancer Patients contract vehicle. IITRI specializes in preclinical drug development services and has...

This is a firm fixed-price delivery order contract awarded by the National Cancer Institute (NCI) to the University Health Network (UHN), doing business as the Toronto General And Western Hospital Foundation, to procure existing clinical and treatment data on at least 500 pediatric cancer patients treated with photon therapy since 2007. The contract, valued at $97,021.21, is part of the NCI's Cancer Genome Atlas (TCGA) program and will support the U.S. Pediatric Photon Therapy Comparison...

This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to Nanoscale Corporation. The $831,900 contract is for the development of &quot;functionalized bimagnetic core/shell Fe/Fe3O4 stealth nanoparticles&quot; for the diagnosis and treatment of cancer. The contract includes two major subcontractors - Xenometrics, LLC, which will conduct toxicology testing, and the...

The National Cancer Institute (NCI) awarded a $293,970 firm fixed-price purchase order to the University Health Network (UHN), doing business as the Toronto General And Western Hospital Foundation, to retrieve existing clinical and treatment data for at least 500 pediatric cancer patients treated with photon therapy since 2007. This data will be used to evaluate photon therapy as a cancer treatment for pediatric patients as part of the U.S. Pediatric Photon Therapy Comparison Cohort Study. The...

This is a cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency, to the University of Illinois. The contract is valued at $761,043.02 and is part of the larger &quot;Toxicology of Drugs Developed for Cancer Patients&quot; indefinite delivery/indefinite quantity (IDIQ) contract vehicle. The purpose of this award is to conduct pre-clinical toxicology studies of a drug candidate, specifically DNA methyltransferase-TdCyd, for potential use in...

This is a federal contract award made by the National Cancer Institute (NCI), a civilian agency, to the University of Pittsburgh. The contract is for the determination of LMP744 (NSC 706744) levels in human plasma and urine samples from an NCI Phase I trial. The contract has a ceiling value of $408,140.33 and a period of performance from April 1, 2017 to June 30, 2022. It is a delivery order contract under the Pharmacokinetic and Pharmacology Evaluations for Cancer Patients master IDIQ. The...

<p>Defense Logistics Agency awarded a $268 firm fixed price delivery order to Amerisourcebergen Drug Corp for 600 mg/60 ml vials of carboplatin. The order is for 60 ml of the chemotherapy drug to be delivered to a location in Conshohocken, Pennsylvania by October 17, 2023. No set-aside provisions were applied to this award placed under an existing vehicle by DLA to supply pharmaceutical products in support of military treatment facilities.</p>